“Drug Discovery in Academia: Some Success Stories” – Vortrag von Prof. Michael E. Jung
The process of drug discovery in academia will be discussed with several examples of prior and ongoing collaborations, with some success stories.
Main focus will be on the two compounds from his lab, which has been approved and are on the market:
1) Xtandi, approved 8/31/12 for the treatment of castration-resistant prostate cancer (CRPC), and
2) Erleada, approved 2/14/18 for the treatment of non-metastatic CRPC.